Focus on biosimilar etanercept – bioequivalence and interchangeability
Fabrizio Cantini,1 Maurizio Benucci2 1Department of Rheumatology, Hospital of Prato, Prato, Italy; 2Rheumatology Unit, Hospital S. Giovanni di Dio, Florence, Italy Background: The recent approval of reference etanercept (re-ETN) biosimilars SB4, GP2015, and HD203 produced relevant changes in the man...
Enregistré dans:
Auteurs principaux: | Cantini F, Benucci M |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2018
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/c540f359f2044d96b0363c07a318a60c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Biosimilars in the management of neutropenia: focus on filgrastim
par: Caselli D, et autres
Publié: (2016) -
Community pharmacists' preparedness for substituting biologics and dispensing biosimilars – Lessons learned from a multinational survey
par: Isabelle Arnet, et autres
Publié: (2021) -
Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product
par: Abdalla A, et autres
Publié: (2017) -
Biosimilars: presumption of guilt
par: Marina Vladimirovna Shestakova, et autres
Publié: (2011) -
Electronic Document Interchange in the Contractual Relationship
par: Shastitko A.Ye., et autres
Publié: (2018)